Related Experiment Videos
Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy
Christopher R McHenry1, Kian Mostafavi, Thomas A Murphy
1Department of Surgery, Case Western Reserve University, School of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA.
Summary
Long-term oral phosphate therapy can lead to tertiary hyperparathyroidism (HPT). Careful monitoring of phosphate, calcium, and parathyroid hormone levels is crucial for managing this rare condition.
Area of Science:
- Endocrinology
- Nephrology
- Metabolic Bone Disease
Background:
- Familial hypophosphatemic rickets (FHR) requires long-term management with phosphate and vitamin D supplementation.
- Prolonged secondary hyperparathyroidism (HPT) can progress to tertiary HPT.
Observation:
- A 35-year-old woman with FHR presented with kidney stones, bone pain, and fatigue after 22 years of treatment.
- Biochemical evaluation revealed elevated parathyroid hormone (PTH), normal calcium, and normal phosphorus, consistent with tertiary HPT.
Findings:
- The patient underwent subtotal parathyroidectomy and thymectomy, followed by postoperative hypocalcemia managed with calcitriol and phosphate.
- Despite treatment adjustments, she experienced recurrent tertiary HPT and kidney stones, necessitating long-term management with cinacalcet, calcitriol, and phosphate.
Implications:
- This case highlights the importance of long-term monitoring for tertiary HPT in patients receiving chronic phosphate and vitamin D therapy.
- Judicious management of phosphate, vitamin D, calcium, and PTH levels is critical for preventing complications and ensuring optimal patient outcomes.